I-Mab (NASDAQ:BDTX) issued its earnings results on Tuesday. The company reported ($4.63) earnings per share for the quarter, missing the consensus estimate of ($1.37) by ($3.26), Fidelity Earnings reports.
BDTX stock traded down $0.65 during midday trading on Wednesday, reaching $25.67. The company had a trading volume of 1,186 shares, compared to its average volume of 323,537. The stock’s 50 day moving average price is $30.58. I-Mab has a fifty-two week low of $17.63 and a fifty-two week high of $41.79.
Several research analysts have commented on the company. Canaccord Genuity assumed coverage on I-Mab in a research report on Monday, February 24th. They issued a “buy” rating and a $50.00 price objective on the stock. Jefferies Financial Group assumed coverage on I-Mab in a research report on Monday, February 24th. They issued a “buy” rating and a $47.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on I-Mab in a research report on Monday, February 24th. They issued an “overweight” rating and a $42.00 price objective on the stock. Finally, Cowen initiated coverage on I-Mab in a research note on Monday, February 24th. They set an “outperform” rating for the company.
I-Mab Company Profile
Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.